Calliditas Therapeutics AB (publ)
CLTEF · OTC
5/31/2025 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $562,887,321 | $4,080,830 | $4,163,434 | $5,549,618 |
| - Cash | $23 | $973,733 | $119,719 | $105,629 |
| + Debt | $44 | $979,133 | $94,506 | $54,555 |
| Enterprise Value | $562,887,342 | $4,086,230 | $4,138,221 | $5,498,544 |
| Revenue | $18 | $1,206,888 | $802,879 | $229,347 |
| % Growth | -100% | 50.3% | 250.1% | – |
| Gross Profit | -$10 | $1,146,425 | $75,495 | $229,347 |
| % Margin | -55.8% | 95% | 9.4% | 100% |
| EBITDA | -$1,718,106 | -$386,350 | -$412,703 | -$494,119 |
| % Margin | -9,435,477% | -32% | -51.4% | -215.4% |
| Net Income | -$102 | -$466,185 | -$39,514 | -$55,306 |
| % Margin | -558.6% | -38.6% | -4.9% | -24.1% |
| EPS Diluted | -0.058 | -8.69 | -7.78 | -9.84 |
| % Growth | 99.3% | -11.7% | 20.9% | – |
| Operating Cash Flow | -$1,099,190 | -$434,655 | -$29,842 | -$51,028 |
| Capital Expenditures | $0 | -$12,788 | -$241 | -$728 |
| Free Cash Flow | -$1,099,190 | -$447,443 | -$30,082 | -$51,756 |